Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Delivered record-high revenues, Adjusted EBITDA1, Adjusted EBITDA per share1 since inceptionGenerated record high cash flow from operations since inceptionProvides 2026 revenues guidance of $490...
-
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
-
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate,...
-
MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end...
-
SAN FRANCISCO, March 10, 2026 (GLOBE NEWSWIRE) -- DianaHR, which offers the first AI-powered HR-as-a-Service platform for SMBs, is proud to announce that its founder and CEO, Upeka Bee, has been...
-
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or...
-
New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
-
Global ALS therapeutics market is expected to grow from USD 1.05B in 2025 to USD 1.96B by 2034 at 11.5% CAGR, driven by new therapies and rising worldwide.
-
MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
-
Delray Beach, FL, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Strategic investments in ASO and siRNA platforms, coupled with breakthrough delivery technologies, position oligonucleotide therapeutics as...